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Purpose: To investigate the role of inflammatory and angiogenic factors in the pathogenesis of diabetic retinopathy, we
determined, in diabetic patients and controls, vitreous and serum concentrations of interferon-induced protein (IP)-10,
monocyte  chemoattractant  protein  (MCP)-1,  macrophage  inflammatory  protein  (MIP)-1α,  MIP-1β,  regulated  upon
activation, normal T-expressed and secreted (RANTES), and vascular endothelial growth factor (VEGF).
Methods: We recruited 36 probands with type 2 diabetes mellitus (15 noninsulin-dependent and 21 insulin-dependent)
and 69 normal controls. Using Cytometric Bead Array Technology, we measured vitreous and serum concentrations of
IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, and VEGF.
Results: In diabetic patients the mean vitreous levels of IP-10, MCP-1 and VEGF were significantly higher compared
normal controls. [IP-10 (pg/mL) 254.84 +/−311.67 versus 78.90 +/− 67.94 (p<0.001); MCP-1 (pg/mL) 1127.14 +/− 738.91
versus 700.80 +/−419.21 (p=0.002); VEGF (pg/mL) 954.98 +/− 2315.09 versus 37.90 +/− 28.51(p<0.001)]. Vitreous
levels of VEGF correlated with vitreous levels of both IP-10 and MCP-1 (p<0.05). MIP-1β, RANTES, and VEGF mean
serum levels were significantly raised in diabetic probands while IP-10, MCP-1, and MIP-1α serum levels showed no
significant  elevation  compared  to  controls  [IP-10  (pg/mL)  346.20  +/−  287.36  versus  328.74  +/−352.35  (p=0.88);
MCP-1(pg/mL) 133.10 +/− 89.10 versus 141.47 +/− 222.15 (p=0.50); MIP-1β (pg/mL) 184.40 +/− 100.20 versus 139.56
+/− 151.38 (p=0.003); RANTES (pg/mL) 51336.23 +/− 19940.31 versus 33629.2 +/− 33301.0 (p=0.002); VEGF (pg/mL)
304.88 +/− 257.52 versus 154.45 +/− 114.78 (p<0.001)].
Conclusions: Our results suggest that in diabetics, there is an upregulation of IP-10, MCP-1, and VEGF in the vitreous
and an upregulation of MIP-1β, RANTES, and VEGF in the serum. These findings support the concept of an angiogenic
and inflammatory element in the development of diabetic retinopathy.
Diabetic retinopathy (DR) is the most common cause of
visual loss in the working population and one of the primary
reasons  for  blindness  worldwide  [1,2].  Diabetic  vessel
changes may induce ischemia, leading to an upregulation of
angiogenic factors in the retina. Aside from the angiogenic
component, there is a large body of evidence indicating that
inflammation is an important event in the pathogenesis of DR
[3]. Leukocytes play a major role in the hypoxic retina by
producing inflammatory cytokines. Evidence from the retinal
ischemia-reperfusion  injury  model  has  demonstrated  that
inflammatory  chemokines  substantially  contribute  to
inducing retinal damage by infiltration of ocular tissue by
leukocytes [4].
A recent study investigated vitreous chemokine levels by
multiplex  bead  analysis  in  58  patients  with  vitreoretinal
disorders  such  as  uveitis,  choroidal  neovascularization,
proliferative vitreoretinopathy, and proliferative DR (PDR)
[5].  The  present  study  is  the  first  to  examine  interferon-
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induced protein (IP)-10, monocyte chemoattractant protein
(MCP)-1,  macrophage  inflammatory  protein  MIP-1α,
macrophage  inflammatory  protein  MIP-1β  regulated  upon
activation, normal T-expressed and secreted (RANTES), and
vascular endothelial growth factor (VEGF) in the vitreous and
serum by multiplex bead analysis in a large number of diabetic
patients compared to controls.
Chemokines are small molecular weight proteins that
guide the migration of responsive cells. Cells attracted by
chemokines  follow  the  direction  of  increasing  chemokine
concentration. In addition to chemoattraction, inflammatory
chemokines cause activation of leukocytes. Chemokines are
categorized into four subgroups: CXC, CC, C, and CX3X
[6].
IP-10 is a CXC chemokine that contributes to the T-
helper type 1immune reactivity. It is secreted by monocytes,
endothelial  cells,  and  fibroblasts,  and  it  promotes
chemoattraction for monocytes and T-cells [7]. Earlier studies
described elevated serum IP-10 concentrations as a risk factor
for  type  1and  type  2  diabetes  mellitus,  and  it  has  been
suggested that vitreous levels of IP-10 are increased in patients
with PDR [8–10]. The present study is the first to determine
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637IP-10  in  the  vitreous  by  Cytometric  Bead  Array  (CBA)
technique.
MCP-1, MIP-1α, MIP-1β, and RANTES are members of
the CC chemokines. MCP-1 recruits immune cells, such as
monocytes. It is produced by retinal endothelial cells and has
been implicated in leukostasis in the hypoxic retina [3,4].
In  animal  models  raised  MCP-1  mRNA  levels  after
retinal  hypoxia  induction  were  determined  [11].  In  rats
increased expression of IP-10, MCP-1, MIP-1α, and MIP-1β
was  found  in  the  hypoxic  inner  retina  [4].  Previous  data
presumed MCP-1 as a potential factor in the proliferative
phase of DR [12].
MIP-1α and MIP-1β are produced by macrophages and
activate  human  granulocytes  such  as  neutrophils,
eosinophils,  and  basophils,  which  may  lead  to  acute
neutrophilic inflammation [13]. MIP-1α and MIP-1β activate
granulocytes  and  induce  the  release  of  proinflammatory
interleukins such as interleukin-1, interleukin-6, and tumor
necrosis factor-α [14,15]. MIP-1α mediates the recruitment of
monocytes. In a mouse model, MIP-1α has been identified as
a  potent  inducer  of  retinal  neovascularization  during
postischemic  inflammation  [16].  The  retinal  ischemia-
reperfusion model showed an upregulation of MIP-1β in the
retinal vessels [4]. We therefore conclude, that MIP-1β may
be involved in the inflammatory element of pathogenesis of
retinal neovascularization. An upregulation of serum levels of
MIP-1α and MIP-1β has been found in type 1 diabetics [17].
RANTES,  produced  by  inflammatory  cells,  retinal
endothelial cells, and retinal pigment epithelial cells, attracts
T-cells,  eosinophils,  and  basophils.  In  addition,  RANTES
activates natural killer cells [18,19]. In tumor model systems,
RANTES seems to be a potent angiogenic factor and may be
involved  in  retinal  neovascularization  in  diabetic  patients
[20,21]. Immunohistochemical investigations of a donor eye
with DR showed the presence of RANTES in the diabetic
retina compared with the retina of a nondiabetic subject [3].
Further, multiplex bead analysis detected RANTES in the
vitreous of patients with PDR [5].
VEGF plays a major role in ocular neovascularization.
VEGF is not only a major mediator of retinal angiogenesis,
but  also  a  potent  inducer  of  vasopermeability  [22].  The
expression of VEGF is upregulated in the retinal pigment
epithelium, glial cells, and vitreous fibroblasts in diabetic
patients [23].
CBA was used to determine vitreous and serum levels of
IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, and VEGF. The
technology has already been used for the measurement of
cytokines and growth factors in vitreous, aqueous humor,
plasma  and  serum  samples  as  well  as  in  tissue  culture
supernatants [24–28]. The determination of cytokines and
growth factors in the vitreous by CBA promises to be of
substantial benefit for ophthalmologic investigations because
numerous parameters can be measured in parallel using a
comparatively small sample volume. Furthermore CBA is
faster and more cost effective than ELISA technology.
For  an  improved  management  of  DR  a  better
understanding of the pathogenesis is crucial. To elucidate the
role  of  inflammatory  and  angiogenic  factors  in  the
development of DR we measured both vitreous and serum
levels of IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, and
VEGF in diabetics and normal controls.
METHODS
Study population: Diabetes was diagnosed according to the
1999  World  Health  Organization  criteria  [29].  For  all
probands,  the  indications  for  pars  plana  vitrectomy  were
diabetic macular edema, epiretinal membranes, and macular
holes. In the diabetes group, 10 had no DR, 10 had non-PDR,
and 16 had PDR. Exclusion criteria were previous intraocular
surgery, earlier intravitreal therapies, photocoagulation in the
preceding three months, uveitis, trauma, vitreous hemorrhage,
and retinal detachment. Informed consent was obtained from
all probands and controls before entering the study.. Research
was performed in accordance with the ethical standards of the
Declaration of Helsinki [30].
Gender and age breakdown: Patients were recruited from the
Department  of  Ophthalmology  of  the  Medical  University
Graz. The population of this case-control study consisted of
36 patients with diabetes mellitus (21 non-insulin dependent,
15 insulin dependent) and 69 non-diabetic control subjects.
The mean age of the 36 diabetic subjects (15 men and 21
women)  was  66.2  years  (SD+-12.2  years).  Twenty-one
probands were insulin-dependent and 15 probands were non-
insulin-dependent.  The  mean  age  of  the  69  non-diabetic
control subjects (23 men and 46 women) was 67.9 years (SD
+-10.3 years). With regard to age no significant difference
between  both  groups  was  observed  (p>0.05).  The  mean
hemoglobin A1c (HbA1c) of the diabetic subjects was 7.40
+-1.11% compared to 5.7 +-0.2% in control subjects (normal
range HbA1c: 4.0 - 6.0%) (p<0.05).
Vitreous—Undiluted  vitreous  samples  were  obtained
during a standard three-port pars plana vitrectomy. After the
patient was anesthetized, vitreous fluid (approximately 1 mL)
was collected via pars plana using a 20- or 23-gauge vitreous
cutter on a 5 mL-syringe after the infusion port was made
without running the fluid on. The specimen was immediately
transferred to a sterile plastic tube on ice. Promptly the sample
was centrifuged at 5000 rpm for 10 min, aliquoted, and stored
at –70 °C until assayed.
Serum—Blood  samples  were  obtained  by  venous
puncture directly before vitrectomy, and immediately placed
on ice. Directly each sample was centrifuged at 3000 rpm for
10 min, aliquoted, and stored at –20 °C until assayed. IP-10,
MCP-1,  MIP-1α,  MIP-1β,  RANTES,  and  VEGF  were
determined in serum as well as in vitreous samples by CBA.
Cytometric  bead  array:  Concentrations  of  six  different
angiogenic  factors  were  determined  in  both  serum  and
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638vitreous samples using the BDTM CBA Flex Set System and
BDTM  Human  Soluble  Protein  Master  Buffer  Kit  (CatNo.
558246, BD Bioscience-PharMingen, San Diego, CA) and the
BDTM CBA Flex Sets for the measurement of IP-10 (CatNo.
558280,  BD  Bioscience-PharMingen),  MCP-1  (CatNo.
558287,  BD  Bioscience-PharMingen),  MIP-1α  (CatNo
558325,  BD  Bioscience-PharMingen),  MIP-1β  (CatNo
558288,  BD  Bioscience-PharMingen),  RANTES  (CatNo
558324, BD Bioscience-PharMingen), and VEGF (CatNo.
558336,  BD  Bioscience-PharMingen)  levels.  Each  BDTM
CBA Flex Set contained one bead population with distinct
fluorescence  intensity  as  well  as  the  appropriate
phycoerythrin (PE) detection reagent and standard. Five bead
populations coated with capture antibodies specific to IP-10,
MCP-1, MIP-1α, MIP-1β, and VEGF were mixed with each
other. The CBA for RANTES was run separately because the
serum  samples  had  to  be  prediluted.  RANTES  was  also
determined  in  serum  and  vitreous  samples  by  ELISA
technique  (Quantikine  RANTES  ELISA,  R&D  Systems,
Minneapolis, MN). The tests were performed according to the
manufacturer’s advice, and samples were run in duplicate.
As previously described [24] the mixed bead populations
as  well  as  the  single  bead  population  for  RANTES  were
incubated with recombinant standards or test samples to form
sandwich  complexes.  After  addition  of  PE-conjugated
detection antibodies, the samples were incubated again and
then resolved in the FL-3 channel of a FACSCalibur flow
cytometer (BD Bioscience). The results were generated in
graphic  and  tabular  format  by  using  the  CBA  analysis
software  (BD  Bioscience-PharMingen).  The  assay
sensitivities were as follows: IP-10 0.4 pg/mL, MCP-1 1.3 pg/
mL, MIP-1α 4.6 pg/mL, MIP-1β 1.4 pg/mL, RANTES 3.2 pg/
mL, and VEGF 39.2 pg/mL.
For the detection of IP-10, MCP-1, MIP-1α, MIP-1β, and
VEGF,  serum  and  vitreous  samples  were  run  without
predilution. For the detection of RANTES, serum samples
were prediluted 1:50, and the vitreous samples were tested
undiluted. The tests were performed and analyzed according
to the manufacturer’s advice. In brief, 50 µL of the five mixed
as well as the single capture beads were mixed with 50 µL of
the  provided  standards  or  samples  (serum,  vitreous)  and
incubated  in  the  dark  for  1  h  at  room  temperature.
Subsequently 50 µL of the mixed as well as the single PE
detection  reagent(s)  were  added,  and  the  samples  were
incubated in the dark for 2 h. After the second incubation step,
the samples were washed, centrifuged (at 200xg for 5 min)
and  resuspended  in  300  µL  of  wash  buffer  as  previously
described [24]. The BD FACSCalibur flow cytometer was
calibrated with setup beads and 300 events were acquired for
each factor and each sample, respectively. Individual analyte
concentrations were indicated by their fluorescence intensities
(FL-2) and were computed by using the respective standard
reference curve and BD CBA software.
Statistical analysis: Data were analyzed using the statistical
package  for  social  sciences  (SPSS  Version  11.0)  for
Windows. Group differences between samples from diabetics
and controls were analyzed using a Student two-tailed t-test
or two-tailed Mann–Whitney test depending on normality
assumptions and homogeneity of variances. All tests were
performed at an error level of 5%. Due to multiple univariate
testing, the Bonferroni correction algorithm of error I level
was applied to retain the global error level at 5%.
RESULTS
The normal range for HbA1c is 4.0 – 6.0%. After adjusting for
age,  sex,  HbA1c,  and  C-reactive  protein,  we  observed
significantly  higher  levels  of  interferon-induced  protein
(IP)-10,  monocyte  chemoattractant  protein  (MCP)-1,  and
vascular  endothelial  growth  factor  (VEGF)  in  vitreous
samples of diabetics compared to those in controls (Table 1).
Mean serum levels of MIP-1β, RANTES, and VEGF
were significantly raised in the diabetic group compared to
controls. Mean IP-10 and MCP-1 serum levels demonstrated
no significant elevation in diabetic probands compared to
controls (Table 2). In both vitreous and serum, MIP-1α levels
were  below  detection  limits.  Vitreous  VEGF  levels  were
positively correlated with vitreous IP-10 and MCP-1 levels
(p=0.001).  HbA1c  levels  in  diabetic  individuals  were
positively correlated with vitreous levels of IP-10, MCP-1,
and VEGF (p<0.05). Only serum levels of MCP-1 were found
to be significantly elevated among insulin dependent diabetic
patients  compared  to  controls,  but  not  among  non-insulin
dependent diabetic patients (164.02 pg/mL ± 85.57 versus
TABLE 1. IP-10, MCP-1, MIP-1Α, MIP-1Β, RANTES, AND VEGF IN THE
VITREOUS SAMPLES OF DIABETIC AND CONTROL PARTICIPANTS (PG/ML)
Diabetics Controls
Mean +/− SD
(Range)
Mean +/− SD
(Range) p-value
IP-10 254.84 (311.67) 78.90 (67.94) <0.001*
10.00–1290.30 10.00–289.33
MCP-1 1127.14 (738.91) 700.80 (419.21) 0.002*
244.27–3330.50 86.97–2177.01
MIP-1α ** ** -
MIP-1β ** ** -
RANTES ** ** -
VEGF 954.98 (2315.09) 37.90 (28.51) <0.001*
10.00–13258.40 10.00–142.63
Interferon-induced  protein  (IP)-10,  monocyte
chemoattractant protein (MCP)-1, macrophage inflammatory
protein  (MIP)-1α,  macrophage  inflammatory  protein
(MIP)-1β, RANTES (regulated upon activation, normal T-
expressed  and  secreted)  and  vascular  endothelial  growth
factor (VEGF) levels in the vitreous of diabetics and control
samples given in picograms per milliliter. The single asterisk
(*) indicates significant after Bonferroni correction p<0.006
(α=0.05) and the double asterisk (**) indicates, that the factor
was below the detection limit. SD means standard deviation.
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639141.47 pg/mL ± 222.15) (p<0.05)). .Vitreous and serum levels
of all investigated parameters did not correlate with the stage
of DR (p>0.0.5).
DISCUSSION
The etiologic key components of DR are hypoxia-induced
inflammation and angiogenesis. Previous studies investigated
either  vitreous  or  serum  levels  of  angiogenic  and
inflammatory factors by multiplex bead analysis [4,5]. In the
present  case-control  study  both  vitreous  and  serum
concentrations of IP-10, MCP-1, MIP-1α, MIP-1 β, RANTES
and VEGF were determined by multiplex bead analysis in 105
patients. After multivariable adjustment, mean levels of IP-10,
MCP-1, and VEGF were found to be significantly increased
in the vitreous of diabetics compared to controls. There was
no significant correlation between vitreous and serum levels
of  diabetic  probands,  suggesting  that  IP-10,  MCP-1,  and
VEGF levels in the vitreous reflected local production. HbA1c
levels in diabetics were positively correlated with vitreous
levels of IP-10, MCP-1, and VEGF. Mean serum levels of
MIP-1β, RANTES, and VEGF showed significant elevation
in diabetics compared to controls.
Increased levels of inflammatory and angiogenic factors
in the vitreous of diabetic probands could be the result of three
pathways. First, it is hypothesized that the breakdown of the
blood-retina barrier leads to raised levels of inflammatory and
angiogenic  factors  in  the  vitreous  of  diabetics  [31,32].  A
second  possibility  is  the  expression  of  inflammatory  and
angiogenic factors by cells within the vitreous fluid, such as
macrophages,  monocytes,  glial  cells,  and  retinal  pigment
TABLE 2. IP-10, MCP-1, MIP-1Α, MIP-1Β, RANTES, AND VEGF IN SERUM SAMPLES FROM DIABETIC AND
CONTROL PARTICIPANTS (PG/ML)
Diabetics Controls
Mean +/− SD
(Range)
Mean +/− SD
(Range) p-value
IP-10 346.20 (287.36) 328.74 (352.35) 0.88
28.06–1586.90 56.06–2809.70
MCP-1 133.10 (89.10) 141.47 (222.15) 0.5
10.00–360.90 10.00–1850.34
MIP-1 α ** ** -
MIP-1β 184.40 (100.20) 139.56 (151.38) 0.003*
43.07–403.61 9.21–1187.32
RANTES 51336.23 (19940.31) 33629.25 (33301.01) 0.002*
5800.00–99600.0 22.30–129100.0
VEGF 304.88 (257.52) 154.45 (114.78) <0.001*
10.00–1196.40 10.00–563.34
Interferon-induced  protein  (IP)-10,  monocyte
chemoattractant protein (MCP)-1, macrophage inflammatory
protein  (MIP)-1α,  macrophage  inflammatory  protein
(MIP)-1β, RANTES (regulated upon activation, normal T-
expressed  and  secreted)  and  vascular  endothelial  growth
factor (VEGF) levels in the serum of diabetics and control
samples given in picograms per milliliter. The single asterisk
(*) indicates significant after Bonferroni correction p<0.006
(α=0.05) and the double asterisk (**) indicates, that the factor
was below the detection limit. SD means standard deviation.
epithelial  cells  [23].  Third,  chemokines  and  angiogenic
factors are expressed by the hypoxic retina as shown in the
retinal  ischemia-reperfusion  model  [4].  These  different
pathways might explain the differences between serum and
vitreous levels of some of the factors.
This is the first study to determine, by multiplex bead
analysis, IP-10 in the vitreous of diabetics . We observed
raised IP-10 levels in the vitreous of diabetic patients, which
is in accordance to the results of Abu-el-Asrar et al., who
found  raised  IP-10  vitreous  levels  in  patients  with  PDR
compared to patients with retinal detachment [33]. It has been
shown that IP-10 expression may be induced by VEGF in
endothelial cells [34]. Our results support this concept as
increased vitreous IP-10 levels were significantly positively
correlated with increased VEGF levels, indicating that there
may be a VEGF-induced release of IP-10 in the vitreous. The
lack of association between VEGF and IP-10 in the serum is
in accordance with previous findings [8,35].
MCP-1 is an angiogenic chemokine and may also be
induced by VEGF [36]. It has been demonstrated that the
angiogenic  effect  of  MCP-1  is  completely  inhibited  by  a
VEGF inhibitor [37]. A positive regulatory feedback loop
between  VEGF  and  MCP-1  expression  by  vascular
endothelial  cells  has  been  suggested  [33].  MCP-1  is  a
mediator of photoreceptor apoptosis in retinal disorders, such
as DR [38]. Immunohistochemical examination of the human
retina has revealed an augmented expression of MCP-1 by
retinal endothelial cells [3]. In the present study significantly
increased  MCP-1  levels  in  the  vitreous  of  diabetics  were
found.  Raised  MCP-1  levels  in  the  vitreous  indicate  DR
activity [39]. Additionally, a significant positive correlation
between MCP-1 and VEGF in the vitreous could be shown.
In accordance with our results, raised levels of MCP-1 in
vitreous humor of patients with vitreoretinal disorders such as
PDR were reported [33]. In insulin-dependent diabetics, our
data  showed  significant  elevation  of  mean  serum  MCP-1
levels compared to controls (data not shown). In noninsulin-
dependent probands, serum MCP-1 levels were not raised
compared to controls. This finding is likely due to our type 2
diabetics having a higher body mass index than our controls.
Chemokines such as MCP-1 are released by adipocytes, and
levels are body mass index correlated [35]. Therefore, the
activity within the adipose tissue may lead to raised MCP-1
serum levels in type 2 diabetics.
In the vitreous, RANTES levels were below the detection
limit in both diabetics and controls, as confirmed by ELISA
technique. In contrast, Banerjee et al. used multiplex bead
analysis and detected RANTES in the vitreous of patients with
PDR [5]. Serum RANTES levels of our diabetic probands
were significantly raised compared to controls. Our findings
are supported by other studies using the ELISA technique
(3,9).
MIP-1α  mediates  the  recruitment  of  macrophages  in
several inflammatory diseases [10]. Vitreous and serum levels
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640of  MIP-1α  and  the  vitreous  level  of  MIP-1β  were  below
detection limits in diabetic and control groups, which is in
accordance  with  previous  studies  [3,33,40].  In  contrast,
Banerjee et al. detected MIP-1β and RANTES in the vitreous
of patients with PDR [5]. In the study of Banerjee et al.,
vitreous hemorrhage was not an exclusion criterion and only
diabetic patients with PDR were included, while in our study
diabetics with and without DR were included and vitreous
hemorrhages  were  excluded.  Serum  concentrations  of
MIP-1β  were  significantly  raised  in  our  diabetic  study
participants. Type 2 diabetes is associated with both T-helper
cells type 1 (MIP-1β) and T-helper cells type 2 (RANTES)-
associated chemokines [35].
VEGF  plays  an  important  role  in  retinal
neovascularization in DR [41]. We determined significantly
increased VEGF levels in vitreous and serum in diabetics
compared to controls, which correlates with that seen in two
other studies [42,43].
Our results support the concept of an inflammatory and
angiogenic element in the development of DR because of
significantly elevated levels of IP-10, MCP-1, and VEGF in
the vitreous. Furthermore, we observed in diabetic patients a
significant  positive  correlation  between  increased  vitreous
levels of IP-10, MCP-1, and VEGF. The cross-talk of these
factors seems to be critical for the development of DR. The
results  show  strong  evidence  for  an  angiogenic  and
inflammatory  component  in  the  development  of  DR.
Additional studies are needed to provide better understanding
of  the  interaction  between  inflammatory  and  angiogenic
factors  since  new  therapeutic  approaches  involve  the
neutralization  of  these  factors  in  the  vitreous  of  diabetic
patients.
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